EP Vantage
EP Vantage
Stop FollowingEP Vantage
View as an RSS Feed
View EP Vantage's Articles BY TICKER:
ABII,
ABT,
AFFY,
ALIM,
ALIOF.PK,
ALNY,
ALTH,
ALXN,
AMGN,
ARIA,
ARQL,
ASTM,
AZN,
BAX,
BCRX,
BMTI,
BMY,
BSNRF.PK,
BSX,
CADX,
CBST,
CELG,
CEPH,
CHTP,
CORT,
COV,
CYPB,
CYTK,
DDSS,
DEPO,
DMYDF.PK,
DNDN,
ECYT,
ESALY.PK,
EW,
FOLD,
FRX,
GE,
GILD,
GSK,
GTXI,
HALO,
HEB,
IMGN,
INHX,
ISPH,
ISTA,
ITMN,
JAZZ,
JNJ,
KG,
LLY,
LMNX,
MDCO,
MDT,
MDVN,
MEDX,
MKGAF.PK,
MNKD,
MYGN,
NAVB,
NEUSF.PK,
NVS,
NYMX,
OMER,
ONXX,
OPOSF.PK,
PARD.PK,
PCYC,
PFE,
PPHM,
RHHBY.OB,
RIGL,
SCR,
SNN,
SNY,
STJ,
SVNT,
SXMDF.PK,
TEVA,
THRX,
TMO,
UCBJY.PK,
UTHR,
VPHM,
VRX,
VVUS,
WILLF.PK,
WMGI,
YMI
- Pfizer Unlikely to Benefit From Surprising New Data on Heart Drug
- Eli Lilly Signals Ongoing Interest in Alzheimer's With Avid Acquisition
- Pharmasset Makes Remarkable Recovery on Hepatitis C Franchise
- Cadence Wins FDA Approval for Painkiller, Now Just Has to Sell It
- Complete Response Letter for Obesity Drug Revives Vivus
- Savient Angers Investors by Flying Solo
- Arena's Weight Loss Drug Battles for Its Life
- Good News Keeps Coming for Amgen With Aranesp Vote
- Jazz Feels No Pain Following FDA Rejection
- Pfizer Is Not Paying a Ransom for King
- Bigger Doors Open for Aveo as Merck Deal Closes
- Novartis Reveals the High Cost of Failure
- Sanofi Takeover Offer for Genzyme: The Pressure Is On
- Actelion: No Rest for the Weary
- Safety Concerns Weigh Heavily on Amag Pharma's Lead Product
- Chelsea Soars on Positive Result for Blood Pressure Drug Second Time Around
- Genzyme Cuts Back for Future Gains: Biotechs Must Revert to Lean Growth
- Good Signs Abound for Forest's New Antibiotic
- Celldex Reeling From Pfizer Breakup
- Future of Genzyme / Isis Pharma's Cholesterol Drug Still Up in the Air
- The Fight for Market Share in Blood Thinners Is On
- Cypress Risks Deepening Disquiet With Another Spending Spree
- Somaxon Will Do More Than Just Collect Checks in P&G Deal
- Lilly's Glimmers of Light Unlikely to Bring Future Growth
- Biogen Pays Pretty Price to Expand ALS Pipeline
- Emergent Seeks Diversity in Trubion Purchase
- Did the Market Overreact to Curis's Latest Setback?
- Merck Plays Down J&J Arbitration but Risk Remains
- Orexigen Steps Up Pace in Obesity Drug Race
- AstraZeneca Hopeful for Positive FDA Call on Blood-Thinner but Doubts Linger
- Sanofi Will Be Concerned About Overpaying for Genzyme
- Safety Concerns Narrow Potential for Valuable Pfizer Pipeline Candidate